Skip to main content
  • Home
  • Heart Failure Management Hub
background background

THIS CONTENT IS FOR HEALTHCARE PROFESSIONALS ONLY

Heart Failure Management Hub

This Heart Failure Management Hub provides a range of valuable educational assets to facilitate the use of SGLT-2 inhibitors and other guideline directed medical therapies as foundational treatment for heart failure (HF).

Supported by an unrestricted educational grant from AstraZeneca.

Discover our Videos and documents

view

Discussions

(16 contents)

hub_video

Discussions

The DELIVER Trial in Brief

EN

author

Carolyn Lam, John McMurray

Prof Lam discusses DELIVER with one of the trial’s lead investigators, Prof McMurray. As well as the key results from DELIVER, they consider how to apply them to HFpEF patients in the real-world.

hub_video

Discussions

DELIVER and DAPA-HF Pooled Analysis in Brief

EN

author

Carolyn Lam, John McMurray

Prof Lam and Prof McMurray put into context the pooled analysis of DELIVER and DAPA-HF and consider whether these results can be extrapolated to the entire HF population, addressing the suitability of patients according to their individual EF.

hub_video

Discussions

Implementation Strategies for GDMT in Respect of the New Guidelines

EN

author

Mikhail Kosiborod, Harriette Van Spall

In this short interview, Dr Kosiborod and Dr Van Spall summarise some of the key changes in guidance following the 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure.

hub_video

Discussions

The PRESERVED-HF Study: Effects of Dapagliflozin

EN

author

Mikhail Kosiborod

In this short presentation on behalf of the investigators, Dr Kosiborod summarises the PRESERVED-HF study, looking at effects of Dapagliflozin on symptoms and functional status in patients with HF and preserved EF.

hub_video

Discussions

Effects of Dapagliflozin in Patients With Chronic Kidney Disease

EN

author

John McMurray

In this presentation of the ESC 2021 poster, 'Effects of Dapagliflozin in Patients With Chronic Kidney Disease, With and Without Heart Failure', Prof McMurray provides a comprehensive overview of the study's background, methods and results.

hub_video

Discussions

Cardio-renal Pathophysiology

EN

author

Kamlesh Khunti, Shelley Zieroth

Prof Khunti outlines what clinicians need to know about the relationship between chronic kidney disease and cardiovascular disease. Prof Heerspink addresses why clinicians should be encouraged to intervene early for patients living with CKD.

hub_video

Discussions

Screening for CKD

EN

author

Kamlesh Khunti, Shelley Zieroth

Prof Khunti addresses the burden of CKD globally, including the prevalence of CKD in patients with type 2 diabetes. The faculty discuss existing tools for screening for CKD, and the recommendations of international guidelines.

hub_video

Discussions

Treatment Options in CKD

EN

author

Shelley Zieroth, Kamlesh Khunti

Dr Zieroth enquires of the latest treatment options for CKD, with Prof Heerspink advising on evidence supporting the use of treatments, whilst Prof Khunti provides insight to the role of initiating SGLT2 therapy, and underlines the urgency to treat.

hub_video

Discussions

Where Do SGLT-2 Inhibitors Fit Into the New Guidelines for HFrEF?

EN

author

Giuseppe Rosano, Andrew Coats

Following the release at ESC 2021 of updated guidelines for the diagnosis and treatment of acute and chronic heart failure, Prof Coats and Prof Rosano address key considerations of where SGLT-2 inhibitors fit into the new guidelines for HFrEF.

hub_video

Discussions

When and How to Initiate SGLT-2 Inhibitors in HFrEF

EN

author

Andrew Coats, Giuseppe Rosano

Following the release at ESC 2021 of updated guidelines for the diagnosis and treatment of acute and chronic heart failure, Prof Coats and Prof Rosano provide a comprehensive update on when and how to initiate SGLT-2 inhibitors.

hub_video

Discussions

Choosing an SGLT-2 Inhibitor – Making an Evidence-based Choice

EN

author

Andrew Coats, Giuseppe Rosano

Following the release at ESC 2021 of updated guidelines for the diagnosis and treatment of acute and chronic heart failure, Prof Coats and Prof Rosano discuss how to make evidence-based choices in the selection of SGLT-2 inhibitors.

hub_video

Discussions

Optimising Treatment of HF

EN

author

Martin R Cowie

In part one of this programme, Prof Cowie introduces the topic and reviews the learning objectives.

hub_video

Discussions

A Review of Recent SGLT2 Inhibitor Data

EN

author

Giuseppe Rosano

Prof Rosano reviews recent SGLT2 trial data, including DAPA – HF, and Emperor Reduced.

hub_video

Discussions

New HFrEF: When and How Should We Initiate an SGLT2 Inhibitor?

EN

author

Javed Butler

Dr Butler presents a case, and considers available treatment strategies, and the optimal approach for HFrEF medications.

hub_video

Discussions

Existing HF-REF: Augmenting the SOC

EN

author

Shelley Zieroth

Dr Zieroth reviews how guideline-directed medical therapy for HFrEF has evolved, and notes that further changes are coming to practice.

hub_video

Discussions

How Will SGLT2 Inhibition Provide the Greatest Impact on HF-REF?

EN

author

Martin R Cowie, Javed Butler, Shelley Zieroth, Giuseppe Rosano

In the final part of this programme, Prof Cowie moderates a discussion with the faculty.

Podcasts

(1 contents)

hub_podcast
20:07

Podcasts

Heart Failure in Focus Podcast

EN

author

Muthiah Vaduganathan

Dr Muthiah Vaduganathan is joined by Prof Scott Solomon for the first episode in this new series, Heart Failure in Focus. Muthu and Scott discuss the DELIVER data which was released at the ESC Congress 2022 in Barcelona.

Symposia

(7 contents)

hub_video

Symposia

SGLT2 Inhibitors: Light at the End of the Tunnel

EN

author

Scott Solomon

Presented, and recorded, at ESC Congress 2022 in Barcelona, our globally-renowned faculty explain how to assess the latest data for SGLT2 inhibitors in heart failure (HF) and how to apply it in real-world practice. 

hub_video

Symposia

SGLT2 Inhibitors Across the Spectrum of Heart Failure

EN

author

John McMurray

Presented, and recorded, at ESC Congress 2022 in Barcelona, our globally-renowned faculty explain how to assess the latest data for SGLT2 inhibitors in heart failure (HF) and how to apply it in real-world practice. 

hub_video

Symposia

Practical Considerations for Treating HF With Mildly Reduced and Preserved EP

EN

author

Carolyn Lam

Presented, and recorded, at ESC Congress 2022 in Barcelona, our globally-renowned faculty explain how to assess the latest data for SGLT2 inhibitors in heart failure (HF) and how to apply it in real-world practice. 

hub_video

Symposia

Implementing Best Practices Across the Spectrum of Heart Failure

EN

author

Muthiah Vaduganathan

Presented, and recorded, at ESC Congress 2022 in Barcelona, our globally-renowned faculty explain how to assess the latest data for SGLT2 inhibitors in heart failure (HF) and how to apply it in real-world practice. 

hub_video

Symposia

The ACC Heart Failure Guidelines 2022: What Did We Learn?

EN

author

Biykem Bozkurt

This symposium, part of Heart Failure Online 2022, provides a succinct overview of the ACC heart failure guideline updates.

hub_video

Symposia

The Future of Guidelines: Towards Personalised Care?

EN

author

Mikhail Kosiborod

This symposium, part of Heart Failure Online 2022, provides a succinct overview of the ACC heart failure guideline updates.

hub_video

Symposia

HFpEF: The Final Chapter in the Heart Failure Story?

EN

author

Andrew Coats

This symposium, part of Heart Failure Online 2022, provides a succinct overview of the ACC heart failure guideline updates.

Roundtables

(3 contents)

hub_video

Roundtables

Ejection Fraction - How Important Is It Today?

EN

author

Martin R Cowie, Richard Hobbs , Kieran Docherty, Bharathi Upadhya

During the first part of this roundtable, chaired by Prof Cowie, our multidisciplinary panel discuss the importance of EF, and analyse survey data.

hub_video

Roundtables

HFrEF and HFpEF Case Review

EN

author

Martin R Cowie, Richard Hobbs , Kieran Docherty, Bharathi Upadhya

During the second part of this roundtable, our multidisciplinary panel discuss two patient cases and their treatment strategies based on recent guidelines and data updates.

hub_video

Roundtables

The Expanding Role of Primary Care in Ongoing HF Management

EN

author

Richard Hobbs , Martin R Cowie, Kieran Docherty, Bharathi Upadhya

During the final part of this roundtable, the panel discuss the role of primary care in ongoing heart failure management.

CME

(2 contents)

hub_course
course_img

CME

SGLT-2 Inhibitors - Another Piece of the Puzzle in Heart Failure

author

Scott Solomon, John McMurray, Carolyn Lam, Muthiah Vaduganathan

Published: 08/09/2022
1 EBAC

hub_course
course_img

CME

Optimising Treatment of HF

author

Martin R Cowie, Javed Butler, Giuseppe Rosano

Published: 24/05/2021
1.00 (EBAC)